Akoya Biosciences $50 million follow-on offering
The stock is listed on Nasdaq
Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 10,005,000 shares of common stock of Akoya Biosciences, Inc for total gross proceeds of approximately $50 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “AKYA.”
Akoya Biosciences is a life sciences technology company that offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response, and that empower clinicians to improve patient outcomes. Akoya’s customers are performing spatial phenotyping to further advance their understanding of diseases such as cancer, neurological and autoimmune disorders and many other therapeutic areas.
The Davis Polk corporate team included partner Deanna L. Kirkpatrick and associates Meaghan Kennedy and Joyce Kim. Partner David R. Bauer and associates David A. Frey, Jordan Khorshad and Anthony Tran provided intellectual property advice. The tax team included counsel Christopher A. Baratta. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.